Sophia GeneticsSOPH +4.00%72 Days Payable is 118.24 as of Mar. 2026, which is 134% above its 10-year median of 50.44. GuruFocus rates SOPH with a GF Score™ of 72/100 and a GF Value™ of $5.03 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 606 Healthcare Providers & Services companies, Sophia Genetics ranks better than 69.31% on this metric.
The historical rank and industry rank for Sophia Genetics's Days Payable or its related term are showing as below:
SOPH'
s Days Payable Range Over the Past 10 Years
Min: 35.99 Med: 50.44 Max: 99.98
Current: 99.98
During the past 8 years, Sophia Genetics's highest Days Payable was 99.98. The lowest was 35.99. And the median was 50.44.
SOPH's Days Payable is ranked better than 69.31% of 606
companies
in the Healthcare Providers & Services industry
Industry Median: 58.205
vs SOPH: 99.98
Sophia Genetics's Days Payable
increased
from Mar. 2025 (53.54) to Mar. 2026 (118.24).
It may suggest that Sophia Geneticsdelayed paying its suppliers.
Sophia Genetics Days Payable Related Terms
Sophia Genetics Days Payable Historical Data
* Premium members only.
The historical data trend for Sophia Genetics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Sophia Genetics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sophia Genetics Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Sophia Genetics's Days Payable distribution charts can be found below:
* The bar in red indicates where Sophia Genetics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Sophia Genetics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sophia Genetics (SOPH) has a Days Payable of 118.24 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sophia Genetics and its competitors. This is 134% above median its historical median of 50.44. Over the past decade, Sophia Genetics' Days Payable has ranged from 35.99 to 99.98. According to the industry distribution chart, Sophia Genetics ranks #186 out of 606 companies in the Healthcare Providers & Services industry, placing it in the top 30.7%.
Is Sophia Genetics' Days Payable too high?
Sophia Genetics' current Days Payable of 118.24 is 134% above median its 10-year median of 50.44. Over the past 10 years, this metric has ranged from a low of 35.99 to a high of 99.98. The Healthcare Providers & Services industry median Days Payable is 58.21. Sophia Genetics' value of 118.24 is 103.1% above this industry median. Based on the distribution chart, Sophia Genetics ranks #186 out of 606 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Sophia Genetics has a GF Score™ of 72/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sophia Genetics' Days Payable compare to WEAV and NRC?
According to the Healthcare Providers & Services industry distribution chart, Sophia Genetics ranks #186 out of 606 companies for Days Payable. This puts Sophia Genetics in the upper half of its industry. The industry median Days Payable is 58.21. Sophia Genetics' value of 118.24 is 103.1% above this benchmark. Historically, Sophia Genetics' own Days Payable has ranged from 35.99 to 99.98 over the past decade. While the company's 10-year median is 50.44 vs. the industry median of 58.21, Sophia Genetics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 58.21, based on 606 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sophia Genetics's current Days Payable of 118.24 is 103.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Sophia Genetics and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 58.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sophia Genetics's current Days Payable is 118.24, which is 134% above median its own 10-year median of 50.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sophia Genetics stock overvalued right now?
Based on GuruFocus' analysis, Sophia Genetics (SOPH) is currently considered Modestly Overvalued. The stock's GF Value™ is $5.03, compared to a current price of $5.98 — trading 18.9% above its estimated fair value. The current Days Payable is 118.24, which is 134% above median its 10-year median of 50.44 and 103.1% above the Healthcare Providers & Services industry median of 58.21. Sophia Genetics' overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Sophia Genetics (SOPH), the current Days Payable is 118.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sophia Genetics (SOPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sophia Genetics stock appears to be overvalued.
The current stock price of $5.98 is trading 18.9% above its estimated GF Value™ of $5.03.
GuruFocus considers Sophia Genetics to be Modestly Overvalued.
Key valuation signals for SOPH:
Days Payable: 118.24 (134% above median its 10-year median of 50.44)
GF Value™: $5.03 vs. price of $5.98 (18.9% above fair value)
Industry Position: 103.1% above the Healthcare Providers & Services median (#186 of 606)
No single metric tells the full story. See the SOPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.
72GF Score
Get the complete analysis for SOPH
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SOPH has been successfully added to your 
